HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

NCT03921294 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Global COVID-19 pandemic prevented further study visits or enrollment.

Conditions

Haemophilic Pseudotumour

Interventions

DRUG: Emicizumab

Sponsor

Indiana Hemophilia &Thrombosis Center, Inc.

Collaborators

[object Object]